Aruna Gullapalli, MD
Psychiatry · Monroe, LANPI 1154303261
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,821 of the $9,943 with a category attached, or 78.7%. 28 manufacturers reported payments, led by AbbVie at 29.8% of the total. Reporting peaked in 2019 at $3,185 and has fallen 70.3% since, to $946 in 2025. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$856
- Alkermes, Inc.$781
- Takeda Pharmaceuticals U.S.A., Inc.$562
- Teva Pharmaceuticals USA, Inc.$441
- plus $3K from 22 others
Across 58 payments — averaging $4782.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$202K
- E.r. Squibb & Sons, L.L.C.$76K
What the payments were for
- Speaking & faculty fees$1,98720%
- Travel & lodging$260%
- Food & beverage$7,82179%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 152 | $2,964 |
| Otsuka America Pharmaceutical, Inc. | 17 | $1,233 |
| Sunovion Pharmaceuticals Inc. | 48 | $856 |
| Alkermes, Inc. | 46 | $781 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $562 |
| Teva Pharmaceuticals USA, Inc. | 23 | $441 |
| Corium, LLC | 19 | $412 |
| Neurocrine Biosciences, Inc. | 16 | $396 |
| Johnson & Johnson | 23 | $361 |
| Lundbeck LLC | 21 | $339 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $274 |
| Axsome Therapeutics, Inc. | 7 | $181 |
| Shire North American Group Inc | 8 | $172 |
| Vanda Pharmaceuticals Inc. | 9 | $171 |
| Supernus Pharmaceuticals, Inc. | 8 | $164 |
| Indivior Inc. | 8 | $159 |
| Ironshore Pharmaceuticals Inc. | 5 | $88 |
| Eisai Inc. | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $62 |
| Noven Therapeutics, LLC | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $37 |
| Merck | 2 | $36 |
| Neos Therapeutics, LP | 1 | $21 |
| Tris Pharma Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$1,124
- ABILIFY MAINTENA$905
How this compares
$9,943 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 124 | $386,914 |
| VraylarCariprazine Hcl | 117 | $169,305 |
| Austedo XrDeutetrabenazine | 14 | $117,609 |
| Abilify MaintenaAripiprazole | 36 | $98,832 |
| CaplytaLumateperone Tosylate | 20 | $36,177 |
| RexultiBrexpiprazole | 21 | $32,984 |
| TrintellixVortioxetine Hydrobromide | 51 | $27,790 |
| Lurasidone Hcl | 50 | $17,935 |
| Divalproex Sodium ErDivalproex Sodium | 297 | $14,499 |
| Ziprasidone Hcl | 161 | $8,832 |
| Divalproex Sodium | 392 | $7,846 |
| Oxcarbazepine | 198 | $7,285 |
| AzstarysSerdexmethylphen/Dexmethylphen | 15 | $6,307 |
| Paliperidone ErPaliperidone | 54 | $6,054 |
| Aripiprazole | 160 | $5,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $361 | $386,914124 claims |
| AbbVieVraylar | $2,964 | $169,305117 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,233 | $131,81657 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $441 | $117,60914 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $274 | $36,17720 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $562 | $32,74464 claims |
| Corium, LLCAzstarys | $412 | $6,30715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Monroe
- Alfredo TorresMonroe$15K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.